Eligo Bioscience Announces Broadest Prokaryotic CRISPR Patent Ever Granted

Eligo Bioscience announced today the issuance by the US Patent and Trademark Office (USPTO) of a landmark CRISPR patent that broadly covers any pharmaceutical composition comprising DNA encoding a CRISPR system to kill prokaryotes – irrespective of the type of CRISPR used, the type of delivery method employed or the type of bacteria targeted. The company is leveraging this technology to address unmet medical needs in immuno-inflammation, oncology and infectious diseases.

The granting of patent #11,491,210 follows a string of major successes for Eligo in recent months, including the issuance of several other strong and broad patents by USPTO.

Speaking to CRISPR Medicine News, Dr. Xavier Duportet, Chief Executive Officer of Eligo Bioscience elaborates on these recent developments, which place Eligo at the forefront of the microbiome in situ gene-editing field.

»Beyond this [patent #11,491,210] being the broadest CRISPR patent issued to date, the USPTO also granted a dozen patents controlled by Eligo in the past months. These include the first ever and similarly broad patents covering the use of base editors to edit the microbiome in situ, and another very broad patent on a pioneering skin platform, leveraging Cutibacterium acnes to bring our unique gene-editing capabilities to the skin.«

As well as strengthening Eligo's leading position within microbiome gene editing, this new patent significantly extends the scope of previously granted patents from the same family (WO2014124226) owned by The Rockefeller University and exclusively licensed to Eligo. This family, which has the earliest priority in the field, has been continuously expanding, with six granted patents in total already and additional grants expected in 2023.

Read the full press release from Eligo Bioscience here.

About Eligo Bioscience

Eligo Bioscience is the world leader in microbiome in vivo gene-editing therapy and is advancing a highly differentiated pipeline of precision genetic medicines to address unmet medical needs in immuno-inflammation and oncology caused by the expression of specific deleterious bacterial genes by our microbiome.

Eligo was founded by scientists from The Rockefeller University and from MIT. Eligo was named a Technology Pioneer by the World Economic Forum and has received venture capital funding from Khosla Ventures and Seventure Partners, and non-dilutive funding from GlaxoSmithKline, the European Commission, CARB-X, and Bpifrance.

For more information about Eligo, visit https://www.eligo.bio/